Vaccinations against infections predisposed by complement deficiencies

Complement deficiencies predispose to an increased susceptibility to infection, in particular caused by Neisseria meningitidis, and to a minor extent by Streptococcus pneumonia and Haemophilus influenza (Table 1, ref 1). While Haemophilus influenzae is only a problem in early childhood and in immunocompromised subjects, the former two are important causes of life-threatening disease in youth and early adolescence or childhood and old age, respectively (refs WA, WB). All three are vaccine-preventable and multivalent and conjugated vaccines should be used (Table WA) - instead of monovalent or polysaccharide vaccines, according to the Advisory Committee on Immunization Practices (ACIP) (ref WA). Guidelines for antimicrobial chemoprophylaxis and for evaluation and management of suspected outbreaks of meningococcal disease are detailed elsewhere (ref WA).

Table WA. Polyvalent conjugated vaccines against Neisseria meningitidis (N.men.), Streptococcus pneumoniae (Str. pneum.) and Haemophilus influenza (H. infl.) - for age licenses see individual by-back information.

Bacteria Serotype Vaccine  Manufacturer
N. men. MenACWY Menactra       Sanofi Pasteur
N. men. MenACWY Menveo Novartis
N. men. MenB Bexsero Novartis
N. men.+H. infl. Hib-MenCY MenHibrix GlaxoSmithKline
Str. pneum. PCV10* Synflorix GlaxoSmithKline
Str. pneum. PCV13** Prevenar13 Wyeth/Pfizer

 

*includes serotypes 1,5,7F in addition to PCV7 serotypes 4,6B,9V,14,18C,19F,23F
**includes serotypes 3,6A,19A in addition to PCV10 serotypes 1,4,5,6B,7F,9V,14,18C,19F,23F

____________________________________

Page References

1. Skattum L, van Deuren M, van der Poll T, Truedsson L. Complement deficiency states and associated infections. Mol Immunol 2011;48:1643-1655.
 

2.  WA. Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62:1-28.

3.  WB. Jefferies JM, Macdonald E, Faust SN, Clarke SC. 13-valent pneumococcal conjugate vaccine (PCV13). Hum Vaccin 2011;7:1012-1018.
 

 aHUS How to use

Svar Life Science AB (formerly Euro Diagnostica)

Mailing address:
P.O. Box 50117
SE-202 11 Malmö
SWEDEN

Visiting address:
Lundavägen 151
212 24 Malmö
SWEDEN

VAT No. SE556564064501

 

Phone: +46 40 53 76 00

info@svarlifescience.com 

Please mail your order to:
order@svarlifescience.com

Please visit our contact section for information about local offices around the world

Shortcuts and important links

Share on Google+ Share on LinkedIn Share on Twitter Share on Facebook



© 2000-2018 Svar Life Science AB
All rights reserved.